Martin specializes in technologies such as the re-targeting of bacterial toxins, vaccines, expression systems, microbial detection assays, cytokine-based therapeutics, and agrochemicals, and represents clients ranging from UK government and blue chip biotech companies through to spin-outs and start-ups. Martin’s principal practice areas include drafting and global prosecution, defence and opposition, freedom-to-operate, and strategic advice. In this regard, Martin has extensive experience in the conduct of Hearings before the European Patent Office, having conducted over 100 Hearings – examples include “HIV peptides” (Adaltis, Abbott Lab, United Biomedical, Institut Pasteur, Bio-Rad Pasteur), “Factor XIII” (Novo Nordisk, Baxter, Aventis Behring), “TACI” (ZymoGenetics, Corixa, HGS), “Omega-3” (Martek Biosciences, Nagase Biochem, Aventis R&T, OmegaTech, Monsanto), "Stomach-action molluscicides" (Young, W.Neudorff GmbH), "Pesticidal compositions" (W.Neudorff GmbH, Bayer CropScience AG), "Aqueous pesticide formulations" (Monsanto, Nufarm Australia Limited, Rhodia Operations), "RNase Ρ detection of pathogenic organisms" (Herrmann; MacLean), "Detection of microbial residues" (DSM IP Assets, Charm Sciences), "One-step detection of antimicrobial residues" (DSM IP Assets, Charm Sciences), "Clonal virus therapeutics" (Wellstat Biologics, Bayer Schering Pharma AG), "Propagation and directed differentiation of CNS stem cells" (Neuralstem Biopharma, Stem Cells Inc.), "Recombinant EPO" (Sterrenbeld Biotechnologie; Polymun Scientific Immunbiologische); "Beverage Preparation" (Sara Lee; MacLean); "Coffee Extract Delivery" (Nestec SA; MacLean); "Beverage System" (Philips IP; MacLean); "Neural Stimulation" (Enteromedics).
Martin is a member of the Life Sciences Committee for the Chartered Institute of Patent Attorneys, and acts as a tutor for the UK and European Qualifying Examinations. He also serves as a lecturer and clinician for the Chartered Institute of Patent Attorneys.
Chambers ranks Martin as a ‘Key Individual’ for biochemistry and biotechnology patents and praises him for being “diligent and proactive, and provides excellent strategic advice” (2011) and "relaxed, personable and approachable" (2012). Martin also comes highly recommended by Legal 500 (2012).
Speaker on Stem Cell Research and Patenting workshop held by the Committee on the Environment, Public Health and Food Safety (ENVI) of the European Parliament